Lars Rydén
Impact in
- Endocrinology, Diabetes and Metabolism top 0.05%
- Diabetes Treatment and Management
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diabetes Management and Research
-
- Acute Myocardial Infarction Research
- Atrial Fibrillation Management and Outcomes
- Cardiac Health and Mental Health
Papers in
-
- Diabetes Treatment and Management 65
- Diabetes, Cardiovascular Risks, and Lipoproteins 55
- Diabetes Management and Research 12
-
- Acute Myocardial Infarction Research 23
- Cardiac Health and Mental Health 12
- Heart Failure Treatment and Management 10
- Co-authors
- Klas Malmberg (41 shared papers)Hans Wedel (11 shared papers)Suad Efendić (6 shared papers)Anna Norhammar (36 shared papers)Anders P. Waldenström (3 shared papers)Johan D. Herlitz (2 shared papers)Peter Nicol (1 shared paper)Lennart Welin (1 shared paper)
- Journals
- European Heart Journal (19 papers)Diabetes Care (18 papers)European Journal of Preventive Cardiology (18 papers)Diabetes and Vascular Disease Research (17 papers)Cardiovascular Diabetology (14 papers)
- Partner nations
- SwedenUnited KingdomGermany
In The Last Decade
Lars Rydén
204 papers receiving 15.7k citations
Lars Rydén's Hit Papers
Peers
Comparison fields: 5 of 132
- Endocrinology, Diabetes and Metabolism 7.6k
- Cardiology and Cardiovascular Medicine 5.1k
- Nephrology 556
- Surgery 2.1k
- Family Practice 116
Countries citing papers authored by Lars Rydén
This map shows the geographic impact of Lars Rydén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Rydén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Rydén more than expected).
Fields of papers citing papers by Lars Rydén
This network shows the impact of papers produced by Lars Rydén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Rydén. The network helps show where Lars Rydén may publish in the future.
Co-authors
The 25 scholars most cited alongside Lars Rydén, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 211 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Hit paper breakdown → | 2019 | 2345 |
| 2 | ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD Hit paper breakdown → | 2013 | 1618 |
| 3 | Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary Hit paper breakdown → | 2007 | 1317 |
| 4 | Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year Hit paper breakdown → | 1995 | 1202 |
| 5 | EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries Hit paper breakdown → | 2015 | 803 |
| 6 | Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity Hit paper breakdown → | 2005 | 798 |
| 7 | European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) Hit paper breakdown → | 2012 | 604 |
| 8 | ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text Hit paper breakdown → | 2006 | 553 |
| 9 | 2001 | 399 | |
| 10 | Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries Hit paper breakdown → | 2019 | 294 |
| 11 | 2004 | 262 | |
| 12 | 2012 | 252 | |
| 13 | Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials Hit paper breakdown → | 2023 | 212 |
| 14 | 2014 | 208 | |
| 15 | Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial Hit paper breakdown → | 2024 | 166 |
| 16 | 2017 | 148 | |
| 17 | 2006 | 147 | |
| 18 | 2010 | 145 | |
| 19 | 2016 | 145 | |
| 20 | 2007 | 144 |
About Lars Rydén
Lars Rydén is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine, Public Health, Environmental and Occupational Health, Nephrology and Surgery, having authored 211 papers that have together received 16.7k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (65 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (55 papers), Acute Myocardial Infarction Research (23 papers), Health Promotion and Cardiovascular Prevention (14 papers), Cardiac Health and Mental Health (12 papers), Diabetes Management and Research (12 papers), Lipoproteins and Cardiovascular Health (11 papers) and Heart Failure Treatment and Management (10 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (7.6k citations), Cardiology and Cardiovascular Medicine (5.1k citations), Nephrology (556 citations), Surgery (2.1k citations) and Family Practice (116 citations). Lars Rydén has collaborated with scholars based in Sweden, United Kingdom and Germany. Frequent co-authors include Klas Malmberg, Hans Wedel, Suad Efendić, Anna Norhammar, Anders P. Waldenström, Johan D. Herlitz, Peter Nicol, Lennart Welin, Linda Mellbin and John Öhrvik. Their work appears in journals such as European Heart Journal, Diabetes Care, European Journal of Preventive Cardiology, Diabetes and Vascular Disease Research and Cardiovascular Diabetology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.